U ntil recently, it was generally assumed that the clinical and biochemical manifestations of familial hypercholesterolemia (FH) were invariably due to a mutation in the low density lipoprotein (LDL) receptor gene. Indeed, every FH homozygote so far examined at the DNA level has been found to have two mutant alleles at the receptor locus, resulting in absent or functionally defective LDL receptors. 1 However, Innerarity et al 2 have now shown that a rare genetic abnormality in apolipoprotein B (apo B)-100, the protein component of LDL responsible for its recognition by the LDL receptor, may give rise to a dominantly inherited increase in plasma LDL concentration (the underlying biochem-between the presence of the mutation and premature heart disease. In a recent study, 5 we screened for the FDB mutation in a group of 173 patients who had been diagnosed clinically as FH heterozygotes and 91 patients with primary type Ha hyperlipoproteinemia considered not to have FH. We identified six FDB heterozygotes in the former group and three in the latter. Five of these nine patients with the apo B mutation had a history of myocardial infarction or severe angina in their 40s or 50s, and six had tendon xanthomas. Since LDL receptor function was not analyzed in any of the nine patients, we could not exclude the possibility that their clinical and biochemical symptoms were the combined effects of two rare mutations, one in the apo B gene and the other in the receptor gene.
In the present work, we provide evidence that LDL receptor function is normal in seven of seven of our FDB patients whose skin fibroblasts were examined in vitro, suggesting that the FDB mutation is capable of giving rise to a clinical disorder indistinguishable from classical FH. By studying the families of index patients heterozygous for FDB, we have also obtained information on the range of clinical and biochemical expression of this mutation.
Methods

Patients and Their Families
Relevant biochemical and clinical findings in the nine hypercholesterolemic FDB heterozygotes have already been reported ( Tables 2  s and 3  5 ). The upper limit of the normal range of plasma total cholesterol concentration was taken to be 6.7 mmol/1 for men and women 6 and 5.4 mmol/1 for children of both sexes aged 2-14 years. 7 The corresponding values for LDL cholesterol were 5.0 and 3.3 mmol/1, respectively. FH was diagnosed on the basis of the criteria recommended by the European Atherosclerosis Society. 6 Plasma lipid and lipoprotein concentrations were determined in all available members of the families of index patients. In those more than 20 years old with FDB, the heart and peripheral arteries were examined clinically, the skin and tendons were examined for xanthomas, and the presence or absence of a corneal arcus was noted. Normal ranges for body weight/height in men and women 8 and in boys and girls 9 were taken from published tables.
Plasma Lipids and Lipoproteins
Plasma lipids and lipoproteins were usually measured in blood samples taken after an overnight fast. When this was not possible (five samples), chylomicrons were removed from the plasma after centrifugation for 2 hours at 43,000 rpm in a Beckman SW 50.1 swing-out rotor (Beckman Instruments, Palo Alto, Calif.). Total cholesterol and triglyceride levels were measured by Technicon AutoAnaryzer methods SE4-0039 PE and SE-0065 FBI. Apo B was measured as described. 10 High density lipoprotein (HDL) cholesterol was measured by a heparin-MnCl 2 precipitation method. 11 Lipoprotein(a) (Lp [a] ) was assayed by a double-antibody enzyme-linked immunoassay, using the TintElize Lp(a) kit (Biopool AB, Umea, Sweden). The procedure was performed according to the manufacturer's instructions and gave a linear standard curve over the range 0-600 mg Lp(a) per liter. Apo E genotypes were determined by amplification by the polymerase chain reaction (PCR), followed by digestion with the enzyme Hha I. 12 After digestion, the DNA fragments were separated by electrophoresis on a 10% nondenaturing polyacrylamide gel for 3 hours and were then visualized on a transilluminator after treatment for 10 minutes with ethidium bromide (0.2 mg/1). The following primers were used for PCR, giving a 223-bp fragment: 1) 5' CTGGGCGCGGA-CATGGAGGACGT 3' and 2) 5' GATGGCGCT-GAGGCCGCGCTCG 3'.
LDL cholesterol concentration was calculated from the Friedewald equation. 13 
Testing for the Familial Defective Apolipoprotein B-100 Mutation
Genomic DNA was prepared from total blood cells after lysis with buffer containing Triton X-100. 14 The FDB mutation was detected by amplifying a segment of genomic DNA spanning the site of the mutation in the apo B gene by PCR, followed by hybridization with radioactive oligonucleotide probes. 5 
Low Density Lipoprotein Binding to Normal Low Density Lipoprotein Receptors
LDL (4=1.019-1.063 g/ml) was prepared by sequential ultracentrifugation, followed by dialysis against 0.15 M NaCl and 1 mM EDTA, pH 7.2. An aliquot of the dialyzed LDL, containing about 4 mg protein, was labeled with iodine-125 by the iodine monochloride method. 15 After dialysis against 0.15 M NaCl and 1 mM EDTA, the labeled sample was sterilized by Millipore filtration (Millipore, Bedford, Mass.) and stored under sterile conditions at 4°C until used. The specific radioactivity of the sample was determined on the day before the experiment. Nonradioactive LDL was added to the labeled sample to give a stock solution (-100 cpm/mg protein) from which serial dilutions were made.
The ability of LDL to bind to normal LDL receptors was determined from the rate of growth of U937 cells in the presence of the test sample of LDL as the sole source of cholesterol in the medium. 16 U937 cells are unable to synthesize cholesterol; hence, their ability to grow in culture is dependent on LDL receptor-mediated uptake of LDL. The results were expressed as percentages of the growth rate induced by normal LDL when the concentrations of normal and test LDLs in the medium were adjusted to give equal concentrations of LDL cholesterol. LDL receptor binding of some LDL samples was also determined from the ability of the test sample to compete with normal 125 I-labeled LDL for binding at 4°C to normal fibroblasts in culture, as described elsewhere.
Assay of Low Density Lipoprotein Receptor Function
Fibroblast cell lines derived from skin biopsies obtained from three normal subjects, from seven FDB heterozygotes, and from M.M. (see Table 2 ) were maintained in monolayer cultures as described previously. 17 All cells used, except those of R.S., were between their fifth and 14th passages. For LDL binding and degradation experiments, 2X10 4 cells were seeded on day 0 into 35-mm plastic wells (Limbro Plates, Flow Laboratories, Irvine, U.K.) containing 1 ml standard growth medium. LDL binding at 4°C and degradation at 37°C were assayed by the procedures described by Goldstein and Brown. 18 All assays were performed on day 7, after the cells had been incubated for 48 hours in a medium in which fetal calf serum was replaced by 5% lipoprotein-deficient human serum. Dissociation constants and maximal binding capacities of LDL to the fibroblasts were calculated from the observed values by Scatchard analysis. Rates of degradation of LDL were corrected for nonenzymic degradation by including a set of "no-cell" blanks carried through the complete procedure.
Haplotype Analysis
Genotypes were determined at six polymorphic sites in the apo B gene. The genotype at the insertiondeletion site in exon 1 was determined by amplifying a segment of the gene by the PCR method with the appropriate oligonucleotide primers. 19 The PCR products were identified by polyacrylamide gel electrophoresis. The Xba I, 20 Ms/71, 21 and^coRI 22 restriction site polymorphisms were analyzed by PCR amplification -followed by gel electrophoresis of the PCR products after digestion with the relevant restriction enzyme. The hypervariable region (HVR) in the 3'-fianking region of the apo B gene 23 was analyzed by PCR followed by electrophoresis. The HVR alleles were identified by comparison with known markers typed by E. Boerwinkle and run in parallel with the amplified samples. The primers used for the PCRs were l)A5flI,5' GGAGACTATTCAGAAGCTAA and 3' GAAGAGCCTGAAGACTGACT; 2) Msp I, 5' GAACTATTGCTAGTGAGGCCA and 3' CTAAGGATCCTGCAATGTCAAGG; 3) EcoRl, 5' CTGAGAGAAGTGTCTTCGAAG and 3' CTC-GAAAGGAAGTGTAATCAC; and 4) HVR, 5' ATGGAAACGGAGAAATTATG and 3' CCTTCT-CACTTGGCAAATAC.
The genotype at the Pvu II restriction site in intron 4 of the apo B gene was determined by Southern blotting. 24 Genotypes at the Ava II 25 and Hindi 26 polymorphic sites in the LDL receptor gene were determined by PCR, followed by digestion of the amplified DNA with the relevant restriction enzyme. The DNA fragments were identified after electrophoresis in 4% NuSieve GTG agarose gels (FMC BioProducts, Rockland, Md.). The primers used for the PCRs were 1) Ava II, 5' TTGCTGCCTGTTTATGA- CAAA and 3' CTCTTGGCTGGGTGAGGTTG; and 2) HincW, 5' CTTATCCACTTGTGTGTCTAG and 3' GATCTCGTACGTAAGCCACAC.
Results
Eight of the FDB heterozygotes described in Reference 5, five of whom had been diagnosed as FH heterozygotes, were available for further study. We have also investigated the families of three of these patients. Five of the eight index patients had tendon xanthomas, and all four men had a history of premature coronary atherosclerosis diagnosed by angiography, with angina pectoris followed by a myocardial infarct (MI) or coronary bypass graft at ages 52 (A.S.), 42 (L.S.), 46 (A.E.), and 57 (R.S.). Table 1 shows the ability of LDL from the eight index patients to bind to normal LDL receptors, expressed in terms of the effect of the test sample of LDL on the growth rate of U937 cells in culture. Growth rate in the presence of each FDB LDL was compared with the growth rate observed in the presence of an equimolar concentration of LDL from a normal subject. Table 1 also shows the results of competitive binding studies of LDL from two FDB patients. Binding abilities were expressed as the relative concentrations of FDB and normal LDL required to displace 50% of the high-affinity binding of radioactive normal LDL to fibroblasts in culture. We also determined direct cell-surface binding of LDL from the daughter of one of the FDB index patients (see below). Values are mean of duplicate observations. Cells from E.K. (father of A.C.) were taken as representative of LDL receptor function in the A.C. family. M.M. was an FH homozygote, known to be homozygous for a mutation in the LDL receptor gene that segregates with clinical FH in his family. 27 The binding affinity of M.M.'s cells for normal LDL, measured in our laboratory over several years, has always been about one third of the normal value.
Binding Efficiency of Low Density Lipoprotein From Familial Defective Apolipoprotein B-100 Patients
N, normal; FDB, familial defective apolipoprotein B-100; FH, familial hypercholesterolemia.
Binding determined by the growth-rate method was markedly reduced in the LDL from all FDB index patients, the values ranging from 28% to 59% of normal. There was no correlation between the reduction in binding efficiency and plasma LDL cholesterol concentration. In the competitive binding studies, the concentrations of FDB LDL required for 50% competition were 2.5 and 2.3 times the corresponding concentrations of normal LDL. Table 2 shows the dissociation constants of receptor binding and the maximal LDL binding capacity (calculated from the gradient of the line and its intercept with the x axis) in the two normal cell lines and in cell lines obtained from seven FDB patients. (We could not establish a cell line from R.D.).
Low Density Lipoprotein Receptor Function in Fibroblasts From Familial Defective Apolipoprotein B-100 Patients
Dissociation constants for LDL binding in four FDB cell lines (E.S., A.S., L.S., and A.E.) were between or below the values obtained from the two normal cell lines. In the remaining three FDB cell lines (E.K., K.F., and R.S.), the dissociation constants were higher than the normal values. The dissociation constant for LDL binding in the M.M. cell lines was about three times the average of the two normal values. Table 2 show the maximum rates of degradation of normal LDL at 37°C by fibroblasts from the seven FDB patients from whom cell lines were established. Rates of degradation by the FDB cells ranged from 1,990 to 2,370 ng LDL protein/4 hr/mg cell protein and were all close to the mean value from the two normal cell lines (2,440 ng/4 hr/mg cell protein).
Expression of the Familial Defective Apolipoprotein B-100 Mutation in the Families of Index Patients
The families of three index patients (A.C, E.S., and A.E.) were examined in detail.
TheA.C. family. Figure 2 shows the pedigree of this family. A.C. was found to be heterozygous for the apo B (Argj^-^Gln) mutation when patients at the Hammersmith Hospital Lipid Clinic with primary hypercholesterolemia (with or without a clinical diagnosis of FH) were screened for FDB. Clinical examination of her cardiovascular system showed no abnormality, but she had borderline thickening of both Achilles tendons. She had a family history of premature heart disease associated with hypertension and MI on her mother's side (see Table 3 ); her father had an MI at age 65. A.C.'s father and her two children were heterozygous carriers of the mutation. Her mother, husband, and maternal aunts and uncles were homozygous for the normal apo B gene. Since her paternal grandmother (11) was normal, the mutation was presumably present in her paternal grandfather (I 2). This man emigrated to England in the 1930s from the town of Solingen, near Dusseldorf. Table 3 shows the biochemical findings in the examined members of this family. Plasma triglyceride and HDL cholesterol concentrations ranged from 0.5 to 2.1 mmol/1 and from 1.0 to 1.7 mmol/1, respectively. Plasma total and LDL cholesterol concentrations were raised in all four affected members of the family, including A.C.'s 2-year-old daughter. Total and LDL cholesterol concentrations were normal in all unaffected members except A.C.'s mother. Plasma apo B concentrations were higher in the four affected members than in any of the unaffected members except A.C.'s mother. LDL from the four FDB heterozygotes bound to normal LDL receptors with markedly reduced efficiency (24-35% of normal). Although the plasma LDL cholesterol concentration was raised in the index patient's mother, receptor binding of LDL from this subject was within the normal range.
The body weight/height ratios of all the members of this family were within the normal range (see "Methods"). The index patient, her father, and her two children had eaten a low-fat, low-cholesterol diet for the previous 2 years. The index patient smoked an average of five cigarettes per day; her father (II 1) was a nonsmoker.
The A.E. family. The pedigree of this family is shown in Figure 3 . The index patient was identified while he was attending the Hammersmith Hospital Lipid Clinic because of primary hypercholesterolemia. He had not been diagnosed as having FH. He had a coronary artery bypass graft after MI at age 46. There was also a strong family history of premature heart disease associated with MI, with or without a history of angina pectoris ( Figure 3 and Table 4 ). Qinical examination showed no tendon or skin xanthomas and no corneal arcus. He had peripheral neuropathy, also present in several of his relatives. This familial disorder was characterized by progressive weakness and loss of sensation in all four limbs, first appearing at age 30-40 years.
The FDB mutation was present in nine examined members of A.E.'s family, including his surviving o-r-a* brother and a paternal uncle. As noted below, the mutation was probably also present in two deceased relatives. In view of the presence of FDB in his father's brother, A.E. presumably inherited the mutation from his father, who died after an MI at age 72 and who had been treated for hypercholesterolemia.
A.E.'s elder brother (III 2) died of an MI at age 31. Since IV 2 had FDB and since his mother was normal, he must have inherited an FDB allele from his deceased father (III 2). Moreover, since IV 2's sister was normal, III 2 must have been heterozygous for the mutation. Table 4 shows the biochemical and clinical details of the A.E. family. Of the nine examined FDB heterozygotes, six (including an 8-year-old boy and a 7-year-old girl) had hypercholesterolemia and seven had increased plasma LDL cholesterol levels. Two of the FDB heterozygotes (IV 8 and V 5) and all 10 examined normal subjects had plasma LDL cholesterol levels within the normal range. Four of the eight adults presumed or proven to be FDB heterozygotes had suffered an MI, one of them (III 2) at age 31. None of the FDB heterozygotes had xanthomas or corneal arcus. The index patient, four of his deceased relatives, and his living paternal uncle had familial peripheral neuropathy, but there was no evidence of linkage between the FDB allele and the mutation responsible for peripheral neuropathy in this family. (Ill 5, age 61, had FDB but did not have peripheral neuropathy.) The index patient and his brother (III 5) had been treated for hypercholesterolemia with diet and cholestyramine. In both, there was a satisfactory response, the plasma total cholesterol levels falling from 7.1 to 4.9 mmol/1 (HI 3) and from 8.7 to 5.9 mmol/1 (III 5).
The body weight/height ratios of all the examined members of the A.E. family were within the normal range. Subjects III 3 and III 5 and all the affected members of generation IV, together with their wives and children, ate a low-fat, low-cholesterol diet. No member of the family was a smoker. For numbering of subjects, see Figure 2 . Apolipoprotein B (apo B) genotypes are +/+, homozygous normal, and + / -, familial defective apolipoprotein B-100 heterozygote; TC, total cholesterol; TG, triglycerides; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; X, xanthomas; NAD, no clinical abnormality detected; C, cancer, NE, not examined; MI, myocardial infarct; CAD, coronary artery disease; HT, hypertension; CVS, cardiovascular system. LDL binding was determined with U937 cells (see "Methods"). Arrow shows the index subject.
( + / -) Indicates familial defective apolipoprotein B-100 heterozygote deduced from the pedigree. All lipid measurements were made before treatment for hyperlipidemia.
'Values in mg/dl. tThickening of skin over Achilles tendons. ^Borderline thickening of Achilles tendons.
The grandparents of A.E., one of whom must have carried an FDB allele, migrated to the Berkshire town of Reading from a village in East Suffolk toward the end of the last century. Since the A.E. family has a very unusual surname, it is possible to gain some idea of the present geographical distribution of the male descendants of I 1 and I 2. A survey of U.K. telephone directories shows that the name occurs 23 times in the Reading area, twice in Suffolk/Norfolk, and three times in London, but nowhere else in England, Wales, Scotland, or Northern Ireland. Thus, it seems likely that most of the descendants of I 1 and I 2 have remained within a few miles of the center of Reading. At ieast seven of the 10 siblings in generation II are known to have descendants, and some of these are known to live in the Reading area. Hence, it is possible that the total number of affected descendants of I 1 and I 2 living in this region (population =150,000) is much greater than the number we have already detected. If so, the localized spread of the mutation originating in eastern Suffolk may exemplify the initial stages of a founder effect.
The E.S. family. The pedigree of this family is shown in Figure 4 . The index patient was found to be hypercholesterolemic when her plasma lipids were measured after x-ray radiograms had shown calcification of her abdominal aorta. She was referred to the Hammersmith Hospital Lipid Clinic, where she was diagnosed clinically as an FH heterozygote. On clinical examination she was found to have a bruit over the right carotid artery. Xanthomas were present in both Achilles tendons and in an extensor tendon of the left hand, but corneal arcus was not present. Her brother had an MI at age 53, followed by coronary artery bypass graft surgery. He has thickening of the left Achilles tendon but no corneal arcus. E.S.'s father died after MI at age 72; her mother died after MT at age 62. Two of E.S.'s sons, her brother, and her brother's son and granddaughter are heterozygous carriers of the FDB mutation. Table 5 shows the clinical and biochemical details of the E.S. family. All six FDB heterozygotes had hypercholesterolemia and raised plasma LDL cholesterol levels. All the normal subjects had normal plasma lipid levels. E.S. and her brother's son (III 5) were treated for hypercholesterolemia by diet and cholestyramine. In both patients there was a positive response, total plasma cholesterol levels falling from Apolipoprotein B (apo B) genotypes are +/+, homozygous normal, and +/-, familial defective apolipoprotein B-100 heterozygote; TC, total cholesterol, TG, trigh/cerides; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; X, xanthoma; d, deceased; MI, myocardial infarct; PN, peripheral neuropathy; CVS, cardiovascular system, NAD, no abnormality detected; C, cancer; CABG, coronary artery bypass graft; t . elevated; PNS, peripheral nervous system. Arrow shows the index subject.
(+/-) Indicates familial defective apolipoprotein B-100 heterozygote deduced from the pedigree. All lipid measurements were made before treatment for hyperlipidemia.
•Values in mg/dl.
11.2 to 7.2 mmol/1 (E.S.) and from 7.9 to 5.6 mmol/1 (III 5).
The body weight/height ratios of all the FDB members of the E.S. family were within the normal range, and all of them ate a low-fat diet. No member of this family was a smoker.
R.S. andJ.S. R.S. and his 26-year-old daughter J.S. are both FDB heterozygotes. In keeping with this, LDL receptor binding of LDL from both subjects is markedly defective. As determined by the U937 cell method, receptor binding of R.S.'s LDL was 58%, and that of J.S.'s was 57% of normal. Moreover, direct binding of J.S.'s LDL to normal human fibroblasts in culture was only 64% of the value obtained with LDL from a normal subject. However, whereas R.S. has hyperlipidemia (plasma total cholesterol=7.1 mmol/1, plasma LDL cholesterol=5.5 mmol/ 1), J.S. is normolipidemic. On repeated determina- tions, her plasma lipid levels have remained within the normal range (total cholesterol=6.1-6.5 mmol/1, LDL cholesterol=4.1-4.9 mmol/1).
Segregation of the Low Density Lipoprotein Receptor Gene
Although five of the eight FDB index patients listed in Table 1 (R.D., K.F., E.S., A.S., and L.S.) had been diagnosed clinically as FH heterozygotes, the results shown in Table 2 indicate that LDL receptor function was within the normal range in all our FDB patients whose cells were available for study. By analyzing the segregation of alleles at the receptor locus in three FDB families, we have obtained further evidence that the clinical findings associated with the FDB mutation are not due to a mutation in the receptor gene. Receptor gene restriction fragment length polymorphisms (RFLPs) detected with NAD LDL-C, low density lipoprotein cholesterol; Apo E, apolipoprotein E; HDL-C, high density lipoprotein cholesterol; CVS, cardiovascular system; NAD, no clinical abnormality discovered; MI, myocardial infarct (age). All subjects in Table 6 were heterozygous for the familial defective apolipoprotein B-100 mutation.
•Values in mmol/1. tValues in mg/dl.
the enzymes Ava II and Hindi were used to establish haplotypes at the receptor locus. Each family was then examined for cosegregation of receptor gene haplotypes with hypercholesterolemia, a raised plasma LDL concentration, and premature heart disease.
The A.C. family. The haplotypes at the receptor locus in 10 members of this family are shown in Figure 2 . Five individuals were heterozygous at both variable sites, but the haplotypes could be deduced without ambiguity in all 10 individuals. Hypercholesterolemia failed to segregate with an allele at the receptor locus in this family, as shown by the haplotypes in IV 1 and IV 2, both of whom were hypercholesterolemic. Subject IV 1 inherited one of the A + H~ alleles present in his grandfather (II 1), but this allele was not present in IV 2.
The A.E. family. Figure 3 shows the receptor gene haplotypes in the A.E. family. Eleven of the 19 examined members were heterozygous at both RFLP sites, but the haplotypes could be deduced in 10 of these and in the deceased brother of the index patient. Inspection of Figure 3 shows that hypercholesterolemia did not segregate with an allele at the receptor locus in this family. Subject IV 2, who was hypercholesterolemic, inherited an A + H~ allele from his father (III 2, who was known to have had hypercholesterolemia), but he transmitted his A~H + allele to his two hypercholesterolemic children (V 1 and V 2). It should be noted that IV 6, who was hypercholesterolemic, inherited his father's A + H~ allele, whereas his brother (IV 8), who was normocholesterolemic, inherited his father's A~H + allele. The E.S. family. Figure 4 shows the haplotypes at the receptor locus in 12 examined members of the E.S. family. Hypercholesterolemia did not segregate with a receptor gene allele in this family. Subject II3, who was hypercholesterolemic, transmitted hisA + Hã llele to both his sons, one of whom (III 5) had hypercholesterolemia, while the other (III 6) was normal. Moreover, III 5 transmitted his A~H + allele to his hypercholesterolemic daughter (IV 1) and his normocholesterolemic son (IV 2).
Plasma Lipoprotein(a) Concentrations and Apolipoprotein E Genotypes in Familial Defective Apolipoprotein B-100 Heterozygotes
In an attempt to find the reasons for the variable expression of the FDB mutation within and between families, we have determined the plasma Lp(a) concentration and the apo E genotypes in all our FDB patients. The values for the A.C., A.E., and E.S. families are shown in Tables 3, 4 , and 5. Values for the remaining five index patients and their two affected relatives are shown in Table 6 .
In the A.C. family, each of the two FDB heterozygotes with the highest plasma LDL cholesterol concentrations had one E4 allele at the apo E locus, whereas the index patient and her father were both E3/E3. In the A.E. family, all nine FDB heterozygotes, including the two normolipidemic subjects (IV 8 and V 5), were homozygous for the E3 allele. All six FDB subjects in the E.S. family had raised plasma LDL cholesterol levels. Five of these were homozygous for the E3 allele, and in one (IV 1), the genotype was E3/E2. In six of the remaining seven FDB subjects shown in Table 6 , the plasma LDL cholesterol levels were raised, but in R.S.'s daughter, the LDL level was within the normal range. There was no correlation between apo E genotype and clinical signs or plasma lipids.
The two FDB men in the A.E. family who had premature Mis had plasma Lp(a) levels of 78 and 34 mg/dl. In contrast, subject II 9, whose Lp(a) level was 17 mg/dl, survived to age 67 without clinical evidence of cardiovascular disease. The plasma HDL cholesterol levels were similar in the three men. In two of the unrelated men with premature MI (A.S. and L.S.), the Lp(a) levels were higher than in any of the other FDB heterozygotes identified in this study. However, the Lp(a) level of subject II 1 of the A.C. family, who had an MI at age 65, was very low.
Analysis of Haplotypes at the Apolipoprotein B Locus
The mutant apo B alleles in the eight unrelated index patients could all be descended from a single ancestral gene carrying the apo B (Arg3^oo-»Gln) mutation, that is, the mutant alleles could be identical by descent. Alternatively, the mutational event could have occurred on more than one occasion in unrelated ancestors of the index patients. To examine this question, we have analyzed haplotypes of the apo B alleles in all our index patients and in some of their family members. The haplotypes were based on six RFLPs extending from the 5' end to the 3'-flanking region of the apo B gene.
A.C., an FDB index patient, was homozygous at all six sites. Hence, in this patient, it was possible to deduce the haplotype of the mutant allele at the apo B locus. The haplotype, designated x, was comprised as follows: insertion-deletion-
, Xba V (X~), EcoRr (E~), and HVR-49. In A.E., A.S., E.S., and R.S., as well as in A.C., the apo B (Arg 3r5O o^'Gln) mutation could be assigned without ambiguity to a chromosome bearing the x haplotype. In R.D., K.F., and L.S., all of whom were heterozygous at one or more of the six variable sites, either there were no available relatives (L.S.) or the genotypes of available relatives were uninformative. However, in each case, the combination of genotypes was consistent with the presence of the apo B mutation on a chromosome with the x haplotype.
Discussion
In all FDB subjects whose LDL we have tested (eight index patients, three FDB relatives of A.C., and R.S.'s daughter), high-affinity binding of LDL to normal LDL receptors was markedly reduced. Binding and degradation of normal LDL by fibroblasts from six index patients and from an FDB member of the A.C. family were, in all cases, close to the values obtained from two normal fibroblast lines. In some FDB lines, receptor function differed slightly from the normal values. However, in view of the wide range of values obtained from different normal fibroblast lines tested at comparable stages of confluence, 28 this is consistent with the presence of normal LDL receptor activity in all FDB subjects whose cells we have examined. Moreover, in three FDB families, hyperlipidemia failed to segregate with a haplotype at the receptor locus based on two polymorphic sites. Taken together, these two independent lines of evidence indicate that defective LDL receptor function did not contribute to the biochemical or clinical abnormalities in any of the FDB subjects tested.
In the present study, we have examined a total of eight index patients and 18 of their FDB relatives. Of these 26 people, 23 (including a 2-year-old girl) had increased plasma LDL cholesterol concentrations ranging from 5.1 to 9.0 mmol/1, seven had premature coronary artery disease, and five had tendon xanthomas. Thus, under certain conditions, the apo B (Arg 3r 5oo-*Gln) mutation is capable of giving rise to all the clinical features of heterozygous FH, including a family history of hypercholesterolemia or early death from heart disease. Indeed, five of our FDB index patients had been diagnosed clinically as FH heterozygotes before they were shown to have the FDB mutation. Thus, our findings are in agreement with those of Schuster et al, 29 who observed premature coronary artery disease and tendon xanthomas in several FDB patients whose cells exhibited normal receptor function in vitro.
It might be expected that hypercholesterolemia due to accumulation of defective LDL particles in the plasma would not respond to drugs that act by inducing LDL receptors. However, in four hypercholesterolemic FDB members of the A.E. and E.S. families, there was a normal response to cholestyramine. This may have been due to increased catabolism of LDL particles carrying apo B-100 encoded in the normal allele at the apo B locus. Such particles would be recognized by LDL receptors and would, therefore, be taken up and catabolized at an increased rate when receptor activity was stimulated.
Identification of the mutation in the DNA of heterozygous carriers, combined with family studies, has revealed a considerable degree of variability in the expression of the FDB mutation, exemplified by the A.E. family. In this family, expression of the mutant gene varied from the absence of clinical or plasma lipid abnormalities in an adult male (IV 8) to death from MI at the age of 31 (III 2). However, variability in the intensity of phenotypic expression may be no greater in FDB than in many other monogenically inherited disorders of metabolism. In some families with FH, it is now possible to identify the mutation in the genome, and thus to diagnose individuals who have inherited a defective LDL receptor gene but who are free from clinical signs and who have normal plasma cholesterol levels. In one such family studied by Hobbs et al, 30 some heterozygotes had normal plasma LDL levels, although the index patient had all the signs of classical homozygous FH.
Presumably, variable expression of a mutant gene is due largely to the presence of other genes and environmental factors that influence the phenorype. There is nothing to suggest that diet, body mass index, or smoking habit contributed to the variability in expression of the apo B mutation in the families that we have studied. Nor was there any consistent relation between apo E genotype and plasma LDL level. In view of the well-established association between plasma Lp(a) concentration and coronary artery disease, 31 we determined Lp(a) levels in the majority of subjects in our study. There was no clear-cut association between Lp(a) level and clinical expression of FDB. In the A.E. family, III 3 and III 5 (Lp[a] levels of 78 and 34 mg/dl, respectively) had premature MI, whereas II 9 (Lp[a] level of 17 mg/dl) has survived to age 67 without clinical evidence of cardiovascular disease. On the other hand, subject II 1 of the A.C. family, whose plasma Lp(a) level was less than 1 mg/dl, had an MI at age 65. To explain the normal plasma LDL levels in some heterozygous carriers of a mutant LDL receptor gene, Hobbs et al 30 postulated the existence of a dominant gene that suppresses hypercholesterolemia in carriers of a mutant LDL receptor gene. We cannot exclude the possibility that a similar suppressor gene was inherited by subjects IV 8 and V 5 of the A.E. family. However, more extensive studies of larger families would be needed to establish whether a suppressor gene is responsible for the normal plasma LDL levels in some FDB heterozygotes. In this regard, R.S.'s daughter, J.S., is of particular interest. In this subject, the plasma LDL level was normal on repeated measurement, yet her LDL bound with decreased efficiency to normal LDL receptors when tested in vitro with U937 cells and by direct binding to skin fibroblasts. This suggests that in J.S. the rate of production of LDL is abnormally low, or that the rate of catabolism of LDL particles containing apo B-100 encoded in her normal apo B allele is abnormally high. It was not feasible to carry out kinetic studies of LDL metabolism in this subject.
The population frequency of the x haplotype cannot be deduced from the known frequencies of its constituent alleles because there is partial linkage disequilibrium between some of the six polymorphic sites (see, for example, References 32 and 33). However, the frequency of the haplotype cannot be greater than that of its least-common allele, HVR-49, which has a frequency of about 0.10 in white populations of European descent. 23 In view of the presence of the five other alleles, not all of which are in linkage disequilibrium, the frequency of the x haplotype must in fact be lower than this value. However, even on the basis of the more conservative assumption, the probability that in five or possibly eight consecutive FDB patients the mutation would occur by chance on a chromosome with the x haplotype is less than 1 in 10
5
. This strongly suggests that the FDB alleles in our index patients are identical by descent. The allele we have called HVR-49 is the 3'/349 allele identified by Boerwinkle et al 23 and is presumably the HVE-48 allele described by Friedl et al. 33 These workers found two FDB patients in a white Austrian population, in both of whom the mutant allele was present on a chromosome with haplotype M + , E~, HVE-48. Hence, it is likely that in these patients, the mutation was also on a chromosome with the x haplotype. It is of interest that Hamalainen et al 34 failed to find a single FDB individual in a screened population of 552 hyperlipidemic Finns, suggesting that the mutation has not occurred in Finland and that the mutant allele has not yet reached the Finnish population from elsewhere.
Our observations of the clinical expression of FDB are important for two reasons. First, they show that a significant proportion, perhaps as many as 5%, of patients diagnosed as FH heterozygotes on clinical grounds have normal LDL receptors and are carriers of the FDB mutation; whether the definition of FH should be extended to include these patients is a matter for discussion. In the second place, the high proportion of FDB men in our study who had premature MI provides the best available clinical evidence that a raised plasma LDL level, without other changes in the plasma lipoprotein pattern, is a risk factor for coronary heart disease.
